AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
ADMA Biologics: MACD Death Cross and Bollinger Bands Narrowing on 15min Chart
ByAinvest
Friday, Oct 3, 2025 3:02 pm ET1min read
ADMA Biologics' 15-minute chart has exhibited a MACD Death Cross and Bollinger Bands Narrowing at 10:00 on 03/03/2025. This technical indicator suggests that the stock price may continue to decline, with a diminishing magnitude of price fluctuations.
Adma Biologics (ADMA), an infectious disease drug developer, experienced a significant technical indicator shift in its 15-minute chart on March 3, 2025, at 10:00 AM. The appearance of a MACD Death Cross and Bollinger Bands Narrowing suggests potential declines in the stock price, with a diminishing magnitude of price fluctuations [1].The MACD Death Cross occurs when the MACD line crosses below the signal line, indicating a bearish trend. The Bollinger Bands Narrowing, where the bands converge, signifies reduced volatility and potential consolidation or trend reversal. These technical indicators suggest that ADMA's stock price may continue to decline, with less fluctuation in price movements.
In the past month, ADMA's stock has dropped by 14.77%, underperforming the Medical sector's gain of 1.97% and the S&P 500's gain of 3.54%. The company is expected to report earnings with an EPS of $0.16, indicating a 6.67% growth compared to the same quarter last year, and revenue of $130.1 million, up 8.56% year-over-year. For the full year, Zacks Consensus Estimates project earnings of $0.57 per share and a revenue of $506.7 million, reflecting changes of +16.33% and +18.82%, respectively, from the preceding year [1].
Analysts and investors should monitor the upcoming earnings disclosure closely. Positive revisions in analyst estimates can indicate confidence in the business performance and profit potential. Empirical research suggests that estimate revisions have a direct correlation with impending stock price performance. The Zacks Rank, a proprietary model that takes these changes into account, provides an actionable rating system. Currently, ADMA carries a Zacks Rank of #3 (Hold), indicating a neutral stance [1].
Valuation-wise, ADMA is trading at a Forward P/E ratio of 25.72, which is a premium compared to the industry average of 18.92. The Medical - Biomedical and Genetics industry, part of the Medical sector, has a Zacks Industry Rank of 80, placing it in the top 33% of all 250+ industries [1].
Investors should keep an eye on these technical indicators and the upcoming earnings report to gauge the potential direction of ADMA's stock price. For the latest recommendations, visit Zacks Investment Research.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet